Sordella, R., Bell, D. W., Haber, D. A. & Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163–1167 (2004).

Article  CAS  PubMed  Google Scholar 

Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113–125 (2018).

Article  CAS  PubMed  Google Scholar 

Choudhury, N. J. et al. Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers. J. Thorac. Oncol. 18, 463–475 (2023).

Article  CAS  PubMed  Google Scholar 

Planchard, D. et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N. Engl. J. Med. 389, 1935–1948 (2023).

Article  CAS  PubMed  Google Scholar 

Passaro, A. et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann. Oncol. https://doi.org/10.1016/j.annonc.2023.10.117 (2023).

Article  PubMed  Google Scholar 

Leighl, N. B. et al. Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: analysis from the CHRYSALIS study. Ann. Oncol. 32, S951–S952 (2021).

Article  Google Scholar 

Noguchi, T. et al. LLPS of SQSTM1/p62 and NBR1 as outcomes of lysosomal stress response limits cancer cell metastasis. Proc. Natl Acad. Sci. USA 120, e2311282120 (2023).

Article  CAS  PubMed  Google Scholar 

Ichihara, E. et al. SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer. Cancer Res. 77, 2990–3000 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karachaliou, N. et al. Common co-activation of AXL and CDCP1 in EGFR-mutation-positive non-small cell lung cancer associated with poor prognosis. EBioMedicine 29, 112–127 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Nukaga, S. et al. Amplification of EGFR wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors. Cancer Res. 77, 2078–2089 (2017).

Article  CAS  PubMed  Google Scholar